Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary malignant mesodermal ovarian sarcomas.

A Gari1, L Souhami, J Arseneau

  • 1Department of Gynecology, McGill University, Montreal, Quebec, Canada.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|February 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma.

Journal of translational medicine·2022
Same author

Reduction of inter-observer contouring variability in daily clinical practice through a retrospective, evidence-based intervention.

Acta oncologica (Stockholm, Sweden)·2020
Same author

Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.

Journal of neuro-oncology·2017
Same author

Thoracic irradiation in 3weeks for limited-stage small cell lung cancer: Is twice a day fractionation really needed?

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2017
Same author

Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.

Clinical oncology (Royal College of Radiologists (Great Britain))·2016
Same journal

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners" [International Journal of Gynecological Cancer 36 (2026) 104753].

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

piR-hsa-8111406 promotes proliferation and serves as a novel biomarker for early detection of ovarian cancer: a multi-center retrospective study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Balancing fertility potential and oncologic and obstetric risks: a vignette study on decision-making in fertility-sparing surgery for early-stage cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Updated pocket guide for integrated risk stratification in endometrial carcinoma: a practical tool based on European Society of Gynecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology 2025 guidelines.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

How long is enough? Immunotherapy duration in mismatch repair deficient endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
See all related articles

Primary malignant mesodermal ovarian sarcomas are rare and aggressive cancers. Current treatments offer limited long-term survival, highlighting the urgent need for novel therapeutic strategies for this rare ovarian cancer.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Surgical Oncology

Background:

  • Primary malignant mesodermal ovarian sarcomas are exceptionally rare gynecologic neoplasms.
  • These tumors are characterized by a dismal prognosis and are frequently diagnosed at advanced stages.
  • Current 5-year survival rates for this condition are notably low.

Purpose of the Study:

  • To analyze the treatment outcomes and survival data of patients with primary malignant mesodermal ovarian sarcoma.
  • To underscore the limitations of existing treatment modalities.
  • To emphasize the critical need for developing innovative treatment strategies.

Main Methods:

  • Retrospective review of ten patients diagnosed with primary malignant mesodermal ovarian sarcoma at a single institution.

Related Experiment Videos

  • Analysis of treatment protocols, including debulking surgery and adjuvant chemotherapy.
  • Evaluation of patient survival data, including median survival and long-term outcomes.

    • Main Results:

    • All ten patients underwent surgical debulking.
    • Ninety percent of patients received adjuvant chemotherapy.
    • The median survival observed was 20 months, with only one patient surviving beyond five years.

    Conclusions:

    • Standard treatment including surgery and chemotherapy yields poor long-term survival for malignant mesodermal ovarian sarcoma.
    • The rarity and aggressive nature of these tumors necessitate urgent exploration of novel therapeutic approaches.
    • Further research into advanced treatment strategies is imperative for improving patient outcomes in this rare ovarian malignancy.